Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk names SVP biopharmaceuticals in US

Promotion for Eddie Williams
Novo Nordisk Eddie Williams

Novo Nordisk has promoted Eddie Williams to senior VP of biopharmaceuticals in the US.

Williams has been with Denmark-based diabetes specialist Novo since 2006, when he joined as corporate VP, biopharmaceuticals in the US, leading the sales and marketing, business development and new product commercialisation unit.

Prior to this role, he was a VP at Novartis in the US, holding responsibility for the sales, respiratory & dermatology business unit. He has also served in a senior sales role at Pharmacia.

Jesper Hoiland, president of Novo Nordisk Inc, the company's US affiliate, commented on the impact Williams has had on Novo's biopharma business in the US.

"That business has flourished under Eddie's experienced leadership,” said Hoiland. His promotion to senior vice president demonstrates the company's focus on, and commitment to, our pipeline of life-changing biological therapies."

4th February 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...